AgomAb Therapeutics (NASDAQ:AGMB) Shares Down 6.3% – Here’s What Happened

AgomAb Therapeutics NV (NASDAQ:AGMB) traded down 6.3% during mid-day trading on Thursday . The company traded as low as $14.00 and last traded at $14.0150. 59,191 shares traded hands during mid-day trading, a decline of 56% from the average daily volume of 134,962 shares. The stock had previously closed at $14.96.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on AGMB shares. HC Wainwright began coverage on AgomAb Therapeutics in a report on Monday, June 22nd. They issued a “buy” rating and a $35.00 price objective for the company. Wall Street Zen cut shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Cantor Fitzgerald started coverage on AgomAb Therapeutics in a research report on Wednesday, August 19th. They issued an “overweight” rating on the stock. B. Riley Financial started coverage on AgomAb Therapeutics in a research note on Thursday, July 23rd. They issued a “buy” rating and a $34.00 target price on the stock. Finally, Piper Sandler initiated coverage on shares of AgomAb Therapeutics in a research report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price objective on the stock. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.50.

AgomAb Therapeutics Stock Performance

The business has a 50 day moving average price of $13.44 and a 200-day moving average price of $12.50.

AgomAb Therapeutics (NASDAQ:AGMB) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. As a group, research analysts anticipate that AgomAb Therapeutics NV will post -1.76 earnings per share for the current year.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.